JP Morgan's double upgrade is a high-conviction contrarian call, but the firm's 0% historical accuracy on CME and the CEO's large insider sell create a conflicting signal — the improving EPS revisions and insider buy provide some fundamental support, but the analyst call alone is not a strong enough catalyst to act on.
Price Chart
Executive Summary
JP Morgan double-upgraded CME Group Inc. from Underweight to Overweight on October 22, 2026, setting a price target of $367, implying 24% upside from the current $295.79. The call is a sharp contrarian pivot from the firm's prior bearish stance, but JP Morgan's track record on CME is poor — 0% accuracy on 6 prior calls with an average return of 5.9%, well below the top-tier firms covering the stock. Consensus is mixed: 11 Buy (69%), 7 Hold (44%), 3 Sell (19%) across 16 analysts, with a mean target of $296.13 — nearly flat to current price. JP Morgan's $367 target is the highest on the Street, well above the median of $298.50 and the high of $337. The double upgrade is a bold outlier, but the firm's low credibility tempers its signal. Insider activity shows a notable buy from director William R. Shepard on September 25 ($78.6K), while CEO Terrence A. Duffy sold $3.94M on September 10 — a mixed signal. Short interest is elevated at 56.6% of off-exchange volume, suggesting bearish positioning. EPS estimates for the current year have been revised up 8 times vs 2 down in the last 30 days, supporting a fundamental improvement narrative. Bottom line: JP Morgan's aggressive upgrade is a high-conviction contrarian call, but the firm's poor historical accuracy and the CEO's large sale warrant caution — the stock's setup is improving, but the analyst signal alone is not a strong catalyst.
Impact Score
Consensus & Targets
Consensus across 16 analysts is 69% Buy (2 strong buy, 9 buy), 44% Hold (7 hold), and 19% Sell (3 sell). The consensus is tilted bullish but not overwhelmingly so, with a notable hold contingent. JP Morgan's upgrade shifts the balance further toward buys.
Current price is $295.79. Mean target is $296.13 (flat), median $298.50, high $337, low $218. JP Morgan's $367 target is 24% above the current price and well above the consensus high of $337, making it the most bullish call on the Street. Implied upside to mean is essentially zero, but to JP Morgan's target it is +24%.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-22 | JP Morgan | upgrade | Overweight | $367.00 |
| 2026-10-14 | Wells Fargo | maintain | Overweight | $315.00 |
| 2026-10-09 | Morgan Stanley | maintain | Overweight | $337.00 |
| 2026-10-07 | Barclays | maintain | Equal-Weight | $281.00 |
| 2026-10-05 | UBS | maintain | Neutral | $270.00 |
| 2026-10-05 | TD Cowen | maintain | Buy | $300.00 |
| 2026-10-02 | Wells Fargo | initiate | Overweight | $301.00 |
| 2026-09-28 | TD Cowen | reiterate | Buy | $292.00 |
| 2026-09-03 | TD Cowen | reiterate | Buy | $292.00 |
| 2026-08-19 | Deutsche Bank | downgrade | Hold | $270.00 |
In the last 30 days, there have been 2 upgrades (including this one) and 0 downgrades. EPS revisions are positive: current-year estimates saw 8 upward revisions vs 2 downward in the last 30 days, and next-year estimates show the same 8-up/2-down pattern. This suggests improving fundamentals and analyst sentiment.
Firm Track Record — JP Morgan
JP Morgan accuracy: 55% on 6091 calls | avg return: 5.4%
Industry benchmark: mean 51% ± 10%. Top tier: ≥61% (mean + 1σ). Based on 12 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| UBS | 100% | 4/4 | 3.1% | top tier |
| RBC Capital | 100% | 6/6 | 7.8% | top tier |
| Deutsche Bank | 100% | 5/5 | 6.7% | top tier |
| Piper Sandler | 89% | 8/9 | 8.5% | top tier |
| Morgan Stanley | 88% | 7/8 | 6.1% | top tier |
| Keefe, Bruyette & Woods | 75% | 6/8 | 7.6% | top tier |
| Barclays | 71% | 10/14 | 5.6% | top tier |
| Oppenheimer | 71% | 5/7 | 3.6% | top tier |
| Citigroup | 60% | 3/5 | 4.9% | above average |
| Raymond James | 50% | 1/2 | 0.7% | below average |
JP Morgan has a 0% accuracy rate on 6 prior CME calls, with an average return of 5.9%, placing it in the 'below average' tier. This contrasts sharply with top-tier firms like UBS (100% on 4 calls), RBC Capital (100% on 6 calls), and Piper Sandler (89% on 9 calls). The firm's poor track record significantly reduces the credibility of this upgrade.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $3.01 | $2.96 — $3.10 | $1.8B | ↑3 ↓0 |
| +1q | $3.31 | $3.00 — $3.61 | $1.9B | ↑1 ↓0 |
| 0y | $12.40 | $12.34 — $12.53 | $7.1B | ↑5 ↓0 |
| +1y | $13.08 | $12.10 — $13.70 | $7.4B | ↑5 ↓0 |
Cross-Platform Signals
Insider trades show a buy from director William R. Shepard on September 25 ($78.6K) — a bullish signal — but CEO Terrence A. Duffy sold $3.94M on September 10, a large sell that weakens the bullish case. Institutional activity is mixed: three large funds (Vontobel, Robeco, Ninety One) trimmed positions by 46-64%, while Mather Group added 71%. Short interest is elevated at 56.6% of off-exchange volume, indicating significant bearish positioning. No congressional trades were reported.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | Institutional Cluster | $305.71 | awaiting T+60 | — | $308.06 (+0.77%) |
Oct 22, 2026 4d ago | 144 | $305.71 | awaiting T+60 | — | $308.06 (+0.77%) |
Oct 22, 2026 4d ago | ANALYST-UPGRADE | $305.98 | awaiting T+60 | — | $308.06 (+0.68%) |
Oct 21, 2026 5d ago | 8-K | $295.79 | awaiting T+60 | — | $308.06 (+4.15%) |
Oct 21, 2026 5d ago | Press Release | $295.79 | awaiting T+60 | — | $308.06 (+4.15%) |
Oct 2, 2026 24d ago | ANALYST-UPGRADE | $263.14 | awaiting T+60 | — | $308.06 (+17.07%) |
Sep 14, 2026 5w ago | Insider Cluster | $275.09 | awaiting T+60 | — | $308.06 (+11.99%) |
Sep 14, 2026 5w ago | Insider Cluster | $275.09 | awaiting T+60 | — | $308.06 (+11.99%) |
Aug 19, 2026 9w ago | ANALYST-DOWNGRADE | — | awaiting T+60 | — | — |
Jul 22, 2026 13w ago | 8-K | $249.24 $289.46 | ▲ +16.14% | ▲ +12.88% | $308.06 (+23.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers